Table 2 Overall survival (OS), progression-free survival (PFS) and time to discontinuations (TTD) of advanced patients with NSCLC receiving osimertinib

From: Treatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC

  

N (%)

OS (median, 95% CI)

P value

PFS (median, 95% CI)

P value

TTD (median, 95% CI)

P value

Overall cohort

 

174 (100)

32.7 (28.5–41.6)

 

16.3 (15.0–19.7)

 

20.2 (16.2–24.3)

 

Age

<65

65 (37.4)

31.4 (24.1–44.5)

0.724

16.0 (13.8–21.7)

0.618

19.7 (15.7– 29.6)

0.812

 

≥65

109 (62.6)

35.9 (26.6–49.7)

 

17.3 (14.1–24.1)

 

20.3 (15.8–25.2)

 

Gender

Male

53 (30.5)

31.4 (26.4–NA)

0.802

17.3 (14.1–27.4)

0.782

20.3 (15.7–29.6)

0.790

 

Female

121 (69.5)

35.3 (25.0–44.5)

 

16.0 (13.8–20.2)

 

19.7 (15.7–24.3)

 

Race/ethnicity

Non-Hispanic White

46 (26.4)

40.2 (32.6–NA)

0.268

17.3 (15.7–26.4)

0.863

20.5 (16.2–58.0)

0.268

 

Non-Hispanic Black

50 (28.7)

21.9 (14.6–NA)

 

15.6 (13.2–21.4)

 

19.7 (14.6–26.6)

 
 

Hispanic

56 (32.2)

35.3 (26.3–NA)

 

16.1 (10.9–24.2)

 

19.6 (11.5–25.2)

 
 

Asian

22 (12.6)

32.7 (21.2–NA)

 

17.1 (10.2–32.7)

 

23.5 (13.9–NA)

 

Smoking

Smoker (Former or active)

77 (44.3)

35.9 (28.6–NA)

0.318

17.3 (15.0–27.4)

0.378

24.2 (16.2–37.5)

0.245

 

Non-smoker

97 (55.7)

29.6 (25.0–44.9)

 

16.3 (12.1–19.7)

 

17.3 (14.5–23.5)

 

BMI (kg/m2)

Underweight (BMI < 18.5)

21(12.1)

17.4 (13.2–NA)

0.015

15.0 (7.8–18.2)

0.006

15.2 (10.6–NA)

0.057

 

Normal weight(BMI 18.5 – 25)

81(46.6)

41.6 (32.6–60.1)

 

21.1 (15.8–28.7)

 

25.2 (17.3–37.5)

 
 

Overweight/obese (BMI > 25)

72 (41.4)

31.4 (24.2–NA)

 

15.7 (11.9–20.2)

 

17.1 (15.4–21.9)

 

Insurance

Commercial

38 (21.8)

32.6 (21.9–NA)

0.644

15.0 (9.3–28.7)

0.767

16.0 (14.5–34.8)

0.145

 

Medicare

95 (54.6)

40.2 (28.5–55.7)

 

17.3 (15.0–21.4)

 

20.8 (17.2–26.4)

 
 

Medicaid

35 (20.1)

29.6 (17.7–NA)

 

16.0 (8.4–27.8)

 

16.5 (13.5–NA)

 
 

Medicare and Medicaid

6 (3.4)

NA

 

NA

 

6.7 (3.5–NA)

 

Household Income by zip code

<50,000

82 (47.1)

29.3 (24.2–47.0)

0.375

17.1 (12.9–21.4)

0.564

17.1 (13.5–24.2)

0.049

 

≥50,000

92 (52.9)

37.5 (28.6–55.7)

 

16.3 (15.0–21.7)

 

21.4 (16.5–37.5)

 

ECOG PS

<2

129 (74.1)

40.2 (32.7–59.7)

< 0.001

19.1 (16.3–26.4)

<0.001

21.9 (19.7–27.7)

<0.001

 

≥2

45 (25.9)

14.6 (10.0–NA)

 

8.3 (6.6–16.1)

 

11.5 (7.5–17.2)

 

Brain metastases

Yes

69 (39.7)

29.3 (24.1–55.7)

0.649

15.6 (12.9–21.1)

0.252

19.6 (14.5–26.1)

0.554

 

No

105 (60.3)

35.3 (28.5–49.7)

 

17.2 (14.6–25.6)

 

20.8 (16.6–26.6)

 

EGFR mutations

Del 19

110(63.2)

37.5 (28.6–55.7)

0.368

17.2 (13.8–26.4)

0.082

24.3(16.0–34.3)

0.025

 

L858R

45 (25.9)

31.4(25.0–NA)

 

16.3 (15.0–20.5)

 

17.3(15.7–24.2)

 
 

Uncommon

19 (10.9)

24.1(10.3–NA)

 

13.8(5.8–NA)

 

14.1(5.67–NA)

 

Adherence

PDC ≥ 80%

14(8.0)

37.5 (29.6–NA)

0.356

21.1(18.5–35.0)

0.569

26.4 (19.7–NA)

0.739

 

PDC < 80%

62(35.6)

31.4(17.7–NA)

 

16.8(12.9–NA)

 

24.3(14.2–NA)

 

Histology

Adenocarcinoma

168(96.6)

32.7 (26.6–41.6)

0.802

16.3 (14.6–19.7)

0.729

19.6(15.8–24.2)

0.733

 

Squamous cell carcinoma

6(3.4)

59.7 (21.3–NA)

 

18.9 (14.6–NA)

 

24.3(20.8–NA)

 

Line of therapy with osimertinib

First line

111 (63.8)

32.7 (26.4–66.0)

0.511

19.7 (17.1–26.6)

0.001

21.9 (17.2–29.6)

0.025

 

Second line or beyond

63 (36.2)

35.0 (21.9–47.0)

 

13.1 (9.4–16.0)

 

15.2 (13.7–25.2)

 
  1. OS Overall survival, CI Confidence interval, PFS Progression-free survival, TTD Time-to-discontinuation, BMI Body-mass index, ECOG Eastern Cooperative Oncology Group, PS Performance status, NA Not available due to insufficient sample size or because the value was not reached, PDC Proportion of days covered.
Back to article page